UB Paderborn / Katalog / Suche / in CDI

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

Gynecologic oncology, 2019-05, Vol.153 (2), p.425-435

2019

Link zum Volltext

Verfügbarkeit prüfen

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

European journal of cancer (1990), 2021-02, Vol.144, p.200-214

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Scientific reports, 2021-02, Vol.11 (1), p.4433-11, Article 4433

2021

Link zum Volltext

Verfügbarkeit prüfen

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

PloS one, 2013-01, Vol.8 (1), p.e52261-e52261

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

Cancers, 2022-02, Vol.14 (4), p.915

2022

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in colorectal cancer

Clinical & translational oncology, 2010-04, Vol.12 (4), p.261-270

2010

Link zum Volltext

Verfügbarkeit prüfen

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

ESMO open, 2019, Vol.4 (2), p.e000444-e000444, Article e000444

2019

Link zum Volltext

Verfügbarkeit prüfen

SEOM guidelines for cervical cancer

Clinical & translational oncology, 2012-07, Vol.14 (7), p.516-519

2012

Link zum Volltext

Verfügbarkeit prüfen

SEOM guidelines for endometrial cancer

Clinical & translational oncology, 2012-07, Vol.14 (7), p.512-515

2012

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of everolimus and radiation for neuroendocrine liver metastases

Endocrine-related cancer, 2021-08, Vol.28 (8), p.541-548

2021

Link zum Volltext

Verfügbarkeit prüfen

RTID-03. A PHASE 1/2 STUDY OF THE WEE1 INHIBITOR DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE +- RADIOTHERAPY IN ADULTS WITH RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v258-v259

2023

Link zum Volltext

Verfügbarkeit prüfen

164: Dynamic Contrast-Enhanced CT and MRI to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation

Radiotherapy and oncology, 2021-10, Vol.163, p.S69-S70

2021

Link zum Volltext

Verfügbarkeit prüfen

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Current oncology reports, 2021-07, Vol.23 (7), p.80-80, Article 80

2021

Link zum Volltext

Verfügbarkeit prüfen

Evolution in epithelial ovarian cancer (OC) trials: Improving accuracy by design

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5534-5534

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5573-5573

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5569-5569

2017

Link zum Volltext

Verfügbarkeit prüfen

Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5595-5595

2018

Link zum Volltext

Verfügbarkeit prüfen

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Current Oncology Reports, 2016-04, Vol.18 (4), p.23, Article 23

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3089-3089

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparative benchmarking of regulatory drug approvals by Food & Drug Administration (FDA): A cross disease comparison with gynecologic malignancies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16584-e16584

2015

Link zum Volltext

Verfügbarkeit prüfen

Current and emerging treatment options in the management of advanced ovarian cancer

Expert opinion on pharmacotherapy, 2016-05, Vol.17 (8), p.1063-1076

2016

Link zum Volltext

Verfügbarkeit prüfen

Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3032-3032

2018

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5564-5564

2016

Link zum Volltext

Verfügbarkeit prüfen

Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5509-5509

2016

Link zum Volltext

Verfügbarkeit prüfen

An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16586-e16586

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

Biomarkers in colorectal cancer

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

SEOM guidelines for cervical cancer

SEOM guidelines for endometrial cancer

A pilot study of everolimus and radiation for neuroendocrine liver metastases

RTID-03. A PHASE 1/2 STUDY OF THE WEE1 INHIBITOR DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE +- RADIOTHERAPY IN ADULTS WITH RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA

164: Dynamic Contrast-Enhanced CT and MRI to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Evolution in epithelial ovarian cancer (OC) trials: Improving accuracy by design

Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors

Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts)

Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma

Comparative benchmarking of regulatory drug approvals by Food & Drug Administration (FDA): A cross disease comparison with gynecologic malignancies

Current and emerging treatment options in the management of advanced ovarian cancer

Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients

An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC)

Suchergebnisse filtern